Dasatinib-Related ChylothoraxYen Min Huang1, Cheng Hsu Wang2, Jen Seng Huang3, Kun Yun Yeh3, Chien Hong Lai3, Tsung Han Wu3, Pei Hung Chang3, Yueh Shih Chang3, Yii Jenq Lan31Chang Gung Memorial Hospital, Clinic of Internal Medicine, Division of Hematology-oncology, Keelung, Taiwan; Chang Gung Memorial Hospital, Clinic of Internal Medicine, Division of Hematology, Linkou, Taiwan
2Chang Gung Memorial Hospital, Clinic of Internal Medicine, Division of Hematology-oncology, Keelung, Taiwan; Chang Gung University Faculty of Medicine, School of Traditional Chinese Medicine, Taoyuan, Taiwan
3Chang Gung Memorial Hospital, Clinic of Internal Medicine, Division of Hematology-Oncology, Keelung, Taiwan
Dasatinib is a potent second-generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The most common adverse event associated with dasatinib therapy is fluid retention, including pleural effusion. Dasatinib-related chylothorax has rarely been reported. The clinical manifestations, pathophysiology, management, and prognosis are not fully understood. Here we report a 40-year-old woman presenting with chylothorax following dasatinib use. We propose the hypothesis of its mechanism as well as offering a review of the relevant literature. Keywords: Dasatinib, Chylothorax, Chronic myeloid leukemia
Dasatinib İlişkili ŞilotoraksYen Min Huang1, Cheng Hsu Wang2, Jen Seng Huang3, Kun Yun Yeh3, Chien Hong Lai3, Tsung Han Wu3, Pei Hung Chang3, Yueh Shih Chang3, Yii Jenq Lan31Chang Gung Memorial Hospital, Clinic of Internal Medicine, Division of Hematology-oncology, Keelung, Taiwan; Chang Gung Memorial Hospital, Clinic of Internal Medicine, Division of Hematology, Linkou, Taiwan
2Chang Gung Memorial Hospital, Clinic of Internal Medicine, Division of Hematology-oncology, Keelung, Taiwan; Chang Gung University Faculty of Medicine, School of Traditional Chinese Medicine, Taoyuan, Taiwan
3Chang Gung Memorial Hospital, Clinic of Internal Medicine, Division of Hematology-Oncology, Keelung, Taiwan
Dasatinib kronik miyeloid lösemi tedavisinde kullanılan etkin bir ikinci kuşak tirozin kinaz inhibitörüdür. Dasatinib tedavisi ile ilişkili en sık görülen yan etki plevral effüzyonu da içeren sıvı retansiyonudur. Dasatinib ile ilişkili şilotoraks nadiren bildirilmiştir. Klinik belirtileri, patofizyolojisi, yönetimi ve prognozu tam olarak anlaşılamamıştır. Burada dasatinib kullanımı sonrasında şilotoraks gelişimi ile başvuran 40 yaşında bir kadın sunulmuştur. Dasatinib
ile ilişkili şilotoraks gelişiminin mekanizmasının yanı sıra, konu ile ilgili literatür derlemesinden de bahsedilmektedir. Anahtar Kelimeler: Dasatinib, Şilotoraks, Kronik miyeloid lösemi
Yen Min Huang, Cheng Hsu Wang, Jen Seng Huang, Kun Yun Yeh, Chien Hong Lai, Tsung Han Wu, Pei Hung Chang, Yueh Shih Chang, Yii Jenq Lan. Dasatinib-Related Chylothorax. Turk J Hematol. 2015; 32(1): 68-72
Corresponding Author: Yii Jenq Lan, Taiwan |
|